Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.55 |
| ▸ | CCR5 | P51681 | 5/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | USP28 | Q96RU2 | 1/20 | 0.52 |
| ▸ | USP25 | Q9UHP3 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.51 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30739242 | 1.00 | KDM1A (0.55) | KDM1ACCR5SLC6A4MAOBALDH1A1 | |
| SCHEMBL8617145 | 0.89 | ERN1 (0.53) | KDM1ACCR5SLC6A4MAOBALDH1A1 | |
| SCHEMBL8619252 | 0.89 | ERN1 (0.53) | KDM1ACCR5SLC6A4MAOBALDH1A1 | |
| SCHEMBL8612822 | 0.89 | ERN1 (0.48) | KDM1ACCR5SLC6A4MAOBALDH1A1 | |
| SCHEMBL8616532 | 0.89 | KDM1A (0.46) | KDM1ACCR5SLC6A4MAOBALDH1A1 | |
| SCHEMBL8617807 | 0.89 | KDM1A (0.46) | KDM1ACCR5SLC6A4MAOBALDH1A1 | |
| SCHEMBL8613905 | 0.86 | ERN1 (0.47) | KDM1ACCR5SLC6A4MAOBALDH1A1 | |
| SCHEMBL29704022 | 0.86 | KDM1A (0.55) | KDM1ACCR5SLC6A4MAOBALDH1A1 | |
| SCHEMBL15057279 | 0.86 | KDM1A (0.55) | KDM1ACCR5SLC6A4MAOBALDH1A1 | |
| SCHEMBL8643887 | 0.85 | ERN1 (0.48) | KDM1ACCR5SLC6A4MAOBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 185 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388575-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO INC (US) | 2025-12-25 | — | — | US | disclosed |
| WO-2024213125-A1 | BRM SELECTIVE DEGRADATION AGENT AND USE THEREOF | 南京再明医药有限公司 | 2024-10-17 | — | — | WO | disclosed |
| WO-2024054955-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024054955-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| CN-117466897-A | Highly selective FGFR2 inhibitors | 深圳福沃药业有限公司 | 2024-01-30 | — | — | CN | disclosed |
| CN-107722996-B | Polymerizable liquid crystal compound and preparation method and application thereof | 北京八亿时空液晶科技股份有限公司 | 2023-06-09 | — | — | CN | disclosed |
| US-11274100-B2 | EP300/CREBBP inhibitor | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-03-15 | — | — | US | disclosed |
| CN-107699252-B | Polymeric liquid crystal compound and preparation method and application thereof | 北京八亿时空液晶科技股份有限公司 | 2021-09-07 | — | — | CN | disclosed |
| US-20210171520-A1 | EP300/CREBBP INHIBITOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-06-10 | — | — | US | disclosed |
| US-20210121453-A1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2021-04-29 | — | — | US | disclosed |
| WO-1994010179-A1 | ARYLBORON ACIDS AS INTERMEDIATES IN THE PRODUCTION OF COMPONENTS OF LIQUID-CRYSTAL MIXTURES | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-05-11 | — | — | WO | disclosed |
| US-5182047-A | FLUORINATED BIPHENYLDIOLE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 1993-01-26 | — | — | US | disclosed |
| EP-0368975-B1 | FLUORINATED BIPHENYLDIOLE DERIVATIVES | MERCK PATENT GmbH (DE) | 1992-12-16 | — | — | EP | disclosed |
| EP-0496896-A1 | CYCLOBUTANECARBOXYLIC ACID DERIVATIVE AND LIQUID CRYSTAL COMPOSITION CONTAINING THE SAME | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 1992-08-05 | — | — | EP | disclosed |
| EP-0394906-A2 | Liquid crystalline composition | MERCK PATENT GmbH (DE) | 1990-10-31 | — | — | EP | disclosed |
| EP-0388141-A1 | Ferroelectric liquid crystal device | SHARP KABUSHIKI KAISHA (JP) | 1990-09-19 | — | — | EP | disclosed |
| EP-0385662-A2 | Heterocycles with inhibitory activity of 5-lipoxygenase | ZENECA LIMITED (GB) | 1990-09-05 | — | — | EP | disclosed |
| EP-0375404-A2 | Heterocyclic derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-06-27 | — | — | EP | disclosed |
| EP-0368975-A1 | FLUORINATED BIPHENYLDIOLE DERIVATIVES. | MERCK PATENT GMBH (DE) | 1990-05-23 | — | — | EP | disclosed |
| WO-1989012039-A1 | FLUORINATED BIPHENYLDIOLE DERIVATIVES | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1989-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11274100-B2 | EP300/CREBBP inhibitor | EP300, CREBBP, CREB1 | KDM1A 216/4885CCR5 3243/4885SLC6A4 3517/4885 |
| US-20250388575-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS, CBR1 | KDM1A 3155/4885CCR5 56/4885SLC6A4 3204/4885 |
| US-20210121453-A1 | SELECTIVE NR2B ANTAGONISTS | GRIN2B, GRIN2A, GRIN3A | KDM1A 4138/4885CCR5 2377/4885SLC6A4 220/4885 |
| US-20210171520-A1 | EP300/CREBBP INHIBITOR | EP300, CREBBP, CREB1 | KDM1A 216/4885CCR5 3243/4885SLC6A4 3517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.